TP73

Summary

TP73 (tumor protein p73, HGNC:12003) is a protein-coding gene on chromosome 1p36.32, encoding Tumor protein p73 (O15350). Participates in the apoptotic response to DNA damage.

This gene encodes a member of the p53 family of transcription factors involved in cellular responses to stress and development. It maps to a region on chromosome 1p36 that is frequently deleted in neuroblastoma and other tumors, and thought to contain multiple tumor suppressor genes. The demonstration that this gene is monoallelically expressed (likely from the maternal allele), supports the notion that it is a candidate gene for neuroblastoma. Many transcript variants resulting from alternative splicing and/or use of alternate promoters have been found for this gene, but the biological validity and the full-length nature of some variants have not been determined.

Source: NCBI Gene 7161 — RefSeq curated summary.

At a glance

• Gene–disease (curated): ciliary dyskinesia, primary, 47, and lissencephaly (Strong, ClinGen)
• GWAS associations: 6
• Clinical variants (ClinVar): 134 total — 4 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 12
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• Transcription factor: yes — 133 downstream targets (CollecTRI)
• MANE Select transcript: NM_005427

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12003
Approved symbol	TP73
Name	tumor protein p73
Location	1p36.32
Locus type	gene with protein product
Status	Approved
Aliases	P73
Ensembl gene	ENSG00000078900
Ensembl biotype	protein_coding
OMIM	601990
Entrez	7161

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 14 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000354437, ENST00000378280, ENST00000378285, ENST00000378288, ENST00000378290, ENST00000378295, ENST00000603362, ENST00000603364, ENST00000604074, ENST00000604194, ENST00000604479, ENST00000604566, ENST00000713570, ENST00000713571, ENST00000713572, ENST00000908821, ENST00000917568, ENST00000917569

RefSeq mRNA: 13 — MANE Select: NM_005427 NM_001126240, NM_001126241, NM_001126242, NM_001204184, NM_001204185, NM_001204186, NM_001204187, NM_001204188, NM_001204189, NM_001204190, NM_001204191, NM_001204192, NM_005427

CCDS: CCDS44049, CCDS44050, CCDS44051, CCDS49, CCDS55566, CCDS55567, CCDS55568, CCDS55569, CCDS59965

Canonical transcript exons

ENST00000378295 — 14 exons

Exon	Start	End
ENSE00000358575	3683060	3683180
ENSE00000733990	3730000	3730148
ENSE00000868857	3682333	3682430
ENSE00003461431	3730927	3731065
ENSE00003496607	3707549	3707791
ENSE00003503102	3727628	3727770
ENSE00003526787	3723354	3723469
ENSE00003637380	3731463	3731556
ENSE00003646577	3727115	3727224
ENSE00003651642	3728129	3728217
ENSE00003659615	3732747	3736201
ENSE00003670865	3722021	3722207
ENSE00003693819	3729327	3729448
ENSE00003848342	3652516	3652641

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 89.66.

FANTOM5 (CAGE): breadth broad, TPM avg 3.9534 / max 593.9393, expressed in 513 samples.

FANTOM5 promoters (17 alternative TSS)

Promoter ID	TPM avg	Samples expressed
306	1.8131	363
307	0.4338	223
308	0.3470	174
301	0.3071	188
302	0.2299	135
304	0.2280	118
305	0.1707	90
303	0.1200	64
315	0.1013	26
312	0.0743	2

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	89.66	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	80.89	gold quality
pancreatic ductal cell	CL:0002079	79.33	silver quality
bronchial epithelial cell	CL:0002328	75.35	gold quality
bronchus	UBERON:0002185	74.05	gold quality
cerebellar hemisphere	UBERON:0002245	73.62	gold quality
cerebellar cortex	UBERON:0002129	73.60	gold quality
right hemisphere of cerebellum	UBERON:0014890	73.59	gold quality
skin of leg	UBERON:0001511	73.32	gold quality
skin of abdomen	UBERON:0001416	73.17	gold quality
cerebellum	UBERON:0002037	71.71	gold quality
zone of skin	UBERON:0000014	71.10	gold quality
esophagus mucosa	UBERON:0002469	70.55	gold quality
lower esophagus mucosa	UBERON:0035834	70.27	gold quality
tendon of biceps brachii	UBERON:0008188	70.15	gold quality
buccal mucosa cell	CL:0002336	69.46	gold quality
myocardium	UBERON:0002349	69.21	gold quality
minor salivary gland	UBERON:0001830	68.21	gold quality
secondary oocyte	CL:0000655	67.83	gold quality
mouth mucosa	UBERON:0003729	66.67	gold quality
saliva-secreting gland	UBERON:0001044	66.63	gold quality
bone marrow cell	CL:0002092	66.32	silver quality
upper arm skin	UBERON:0004263	65.21	gold quality
cardiac muscle of right atrium	UBERON:0003379	64.96	gold quality
left ventricle myocardium	UBERON:0006566	64.44	gold quality
fallopian tube	UBERON:0003889	64.12	gold quality
vagina	UBERON:0000996	63.95	gold quality
nasal cavity mucosa	UBERON:0001826	63.43	gold quality
nasal cavity epithelium	UBERON:0005384	63.40	gold quality
prostate gland	UBERON:0002367	62.49	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.12
E-CURD-10	no	15.60

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

133 targets.

Target	Regulation
ABCB1	Unknown
ADA	Activation
ADAM2
AFP
ALB
AP1	Unknown
APOD
APP
AQP1
AQP3	Unknown
ATG5
AVP
BAG1
BAK1
BAX	Unknown
BBC3	Activation
BCL2
BDKRB2
BID	Activation
BIK
BIRC5	Unknown
CABLES1	Unknown
CADM1
CASP1	Activation
CASP2
CASP3	Activation
CASP8AP2
CCNB1	Repression
CCND1	Repression
CCND3

JASPAR motifs

Motif	Name	Family
MA0861.1	TP73	p53-related factors
MA0861.2	TP73	p53-related factors

JASPAR matrix evidence (PMIDs): PMID:23243311

Upstream regulators (CollecTRI, top): BHLHE40, CEBPZ, E2F1, E2F3, E2F4, EGR1, EP300, HBP1, HMGB2, IRF1, JUN, KAT2B, KAT5, MYC, MYCN, MYF6, MYOD1, NKX3-1, SIRT1, SP1, STAT1, TBXT, TFAP2A, TP53, TP63, TP73, YY1, ZEB1

miRNA regulators (miRDB)

89 targeting TP73, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-1825	99.72	68.11	1089
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-4649-3P	99.56	66.90	1783

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• expression of p73 in colorectal carcinoma (PMID:11675903)
• Frequent allelic losses on the short arm of chromosome 1 and decreased expression of the p73 gene at 1p36.3 in squamous cell carcinoma of the oral cavity (PMID:11788901)
• DNA damage-induced acetylation potentiates the apoptotic function of p73 by enhancing the ability of p73 to selectively activate the transcription of proapoptotic target genes (PMID:11804596)
• data establish a relationship between p73 gene expression and neuroblastic tumor differentiation and point out a role for the p73 gene in sympathetic neuronal differentiation (PMID:11839584)
• regulated by c-Abl through p38 MAP kinase pathway (PMID:11840343)
• interaction with c-myc and MM1 (PMID:11844794)
• Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. (PMID:11844800)
• data seem to indicate that DeltaNp73 is a crucial gene in neuroblastoma pathogenesis (PMID:11859407)
• overexpression in malignant and premalignant lesions suggests role in oncogenic process in cervical epithelium (PMID:11870517)
• Induction of p57(KIP2) expression by p73beta (PMID:11891335)
• Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. (PMID:11909952)
• loss of reduced TP73 transcript expression through promoter hypermethylation may contribute to the tumorigenesis of oligodendroglial tumors (PMID:11920588)
• Identification and characterization of HIPK2 interacting with this protein and modulating functions of the p53 family in vivo (PMID:11925430)
• p63 and p73 expression may represent an early event in head and neck squamous carcinoma tumorigenesis and may function as oncogenes in the development of these tumors. (PMID:11957139)
• p73 expression is primarily mediated through binding of E2F1 (PMID:11988839)
• upregulation by ascorbic acid (PMID:12023887)
• DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. (PMID:12032848)
• HCMV-mediated inhibition of apoptosis only occurs in p73-expressing cells (PMID:12034725)
• data suggest that p73 stimulates the transcription of the YB-1 promoter by enhancing recruitment of the c-Myc-Max complex to the E-box (PMID:12080043)
• Mouse DDA3 gene is a direct transcriptional target of p73 in transfection assays (PMID:12082536)
• Overexpression of p73beta led to the apoptosis of Hela cells and enhancement of naphthoquinone analog induced cell death. (PMID:12095638)
• is regulated by protein kinase C delta (PMID:12097319)
• p73 gene inactivation might play an important role in the pathogenesis of acute lymphoblastic leukemia . The main mechanism of the loss expression would be the hypermethylation of p73 gene. (PMID:12133444)
• role in expression of DAN during cisplatin-induced cell death and osteoblast differentiation (PMID:12150978)
• identification of direct target genes combining DNA microarray and chromatin immunoprecipitation analyses (PMID:12213815)
• deletion or methylation of p73 is associated with B cell non-Hodgkin’s lymphomas (PMID:12353228)
• Overexpression of p73 in vascular smooth muscle cells results in decreased cell cycle transit accompanied by apoptosis. (PMID:12388104)
• p73 has roles as a specific dominant negative transcriptional repressor of the cell cycle inhibitor gene p21 blocking p53-mediated apoptosis (PMID:12427762)
• No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. (PMID:12430182)
• p53 DNA-binding domain plays a role in p73 interaction. (PMID:12519788)
• This protein and p53 interact with CTF2 and regulate HMG1 gene expression. (PMID:12534345)
• p73 isoforms affect the retinoblastoma protein (RB) tumor suppressor pathway independent of p53 (PMID:12584188)
• p73 has a role in apoptosis that requires PMS2 protein (PMID:12601175)
• transcriptional activation function of p73 is specifically targeted by E1A through a mechanism involving p300/CBP proteins during the process of transformation and that p73 may have a role to play as a tumor suppressor (PMID:12639967)
• modulation of level by cyclin G via a negative feedback reglation (PMID:12642871)
• p73 is phosphorylated in a cell cycle-dependent manner and negatively regulated by cyclin-dependent kinases (PMID:12676926)
• p53 and p73alpha have roles in cell migration (PMID:12750388)
• TP73 is an important E2F1 apoptotic target gene in DNA damage response. Acetylation is required for E2F1 recruitment on the P1p73 promoter and for its transcriptional activation. (PMID:12766778)
• Adenovirus-mediated p73 overexpression results in a strong induction of apoptosis in pancreatic adenocarcinoma. (PMID:12782576)
• Analysis of gene expression level profiles showed that parental cell line undergoes apoptosis through an E2F1/p73-dependent pathway while its drug resistant variant evades it. (PMID:12789260)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tp73	ENSDARG00000017953
mus_musculus	Trp73	ENSMUSG00000029026
rattus_norvegicus	Tp73	ENSRNOG00000024707
drosophila_melanogaster	p53	FBGN0039044

Paralogs (2): TP63 (ENSG00000073282), TP53 (ENSG00000141510)

Protein

Protein identifiers

Tumor protein p73 — O15350 (reviewed: O15350)

Alternative names: p53-like transcription factor, p53-related protein

All UniProt accessions (2): O15350, A0A0C4DFW9

UniProt curated annotations — full annotation on UniProt →

Function. Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein. Is an activator of FOXJ1 expression. It is an essential factor for the positive regulation of lung ciliated cell differentiation.

Subunit / interactions. Found in a complex with p53/TP53 and CABLES1. The C-terminal oligomerization domain binds to the ABL1 tyrosine kinase SH3 domain. Interacts with HECW2. Isoform Beta interacts homotypically and with p53/TP53, whereas isoform Alpha does not. Isoform Gamma interacts homotypically and with all p73 isoforms. Isoform Delta interacts with isoform Gamma, isoform Alpha, and homotypically. Isoforms Alpha and Beta interact with HIPK2. Isoform Alpha interacts with RANBP9. Isoform Beta interacts with WWOX. Interacts (via SAM domain) with FBXO45 (via B30.2/SPRY domain). Interacts with YAP1 (phosphorylated form). Interacts with HCK (via SH3 domain); this inhibits TP73 activity and degradation. Interacts (via SAM domain) with NQO1; this interaction is NADH-dependent, stabilizes TP73 in response to oxidative stress and protects it from ubiquitin-independent degradation by the 20S proteasome. (Microbial infection) Interacts with Epstein-Barr virus protein EBNA6; this interaction inhibits TP73-mediated apoptotic pathway.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue. Expressed in the respiratory epithelium.

Post-translational modifications. Isoform alpha (but not isoform beta) is sumoylated on Lys-627, which potentiates proteasomal degradation but does not affect transcriptional activity. Phosphorylation by PLK1 and PLK3 inhibits the transcription regulator activity and pro-apoptotic function. Higher levels of phosphorylation seen in the brain from patients with Huntington disease. Polyubiquitinated by RCHY1/PIRH2; leading to its degradation by the proteasome.

Disease relevance. Ciliary dyskinesia, primary, 47, and lissencephaly (CILD47) [MIM:619466] A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. CILD47 is an autosomal recessive form characterized by onset soon after birth or in early childhood. Affected individuals also have neurologic features, such as impaired intellectual development and central hypotonia, associated with structural brain abnormalities, most notably lissencephaly and thin or absent corpus callosum. No situs abnormalities have been observed. The disease is caused by variants affecting the gene represented in this entry.

Cofactor. Binds 1 zinc ion per subunit.

Domain organisation. Possesses an acidic transactivation domain, a central DNA binding domain and a C-terminal oligomerization domain that binds to the ABL1 tyrosine kinase SH3 domain. The PPxY motif mediates interaction with WWOX.

Induction. Not induced by DNA damage. Isoforms lacking the transactivation domain block gene induction.

Miscellaneous. Maps to a chromosome region frequently mutated in diverse cell lines of human cancer. Appears not to be frequently mutated in human cancers, in contrast to p53/TP53. Hemizygosity is observed in neuroblastoma and oligodendroglioma. Activated and stabilized by interaction with RANBP9. Produced by alternative splicing of isoform Alpha. Produced by alternative splicing of isoform Alpha. The splicing of exon 11 results in a frameshift from the original reading frame. Produced by alternative splicing of isoform Alpha. Produced by alternative splicing of isoform Alpha. The splicing of exon 11 results in a frameshift from the original reading frame. The splicing of exon 13 reverts the reading frame to the sequence of isoform Alpha. Produced by alternative splicing of isoform Alpha. Produced by alternative promoter usage. Produced by alternative splicing of isoform dN-Alpha. Produced by alternative splicing of isoform dN-Alpha.

Similarity. Belongs to the p53 family.

Isoforms (12)

UniProt ID	Names	Canonical?
O15350-1	Alpha	yes
O15350-2	Beta
O15350-3	Gamma
O15350-4	Delta
O15350-5	Epsilon
O15350-6	Zeta
O15350-8	dN-Alpha
O15350-9	dN-Beta
O15350-10	dN-Gamma
O15350-11	10
O15350-12	11
O15350-13	12

RefSeq proteins (13): NP_001119712, NP_001119713, NP_001119714, NP_001191113, NP_001191114, NP_001191115, NP_001191116, NP_001191117, NP_001191118, NP_001191119, NP_001191120, NP_001191121, NP_005418* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001660	SAM	Domain
IPR002117	p53_tumour_suppressor	Family
IPR008967	p53-like_TF_DNA-bd_sf	Homologous_superfamily
IPR010991	p53_tetrameristn	Domain
IPR011615	p53_DNA-bd	Domain
IPR012346	p53/RUNT-type_TF_DNA-bd_sf	Homologous_superfamily
IPR013761	SAM/pointed_sf	Homologous_superfamily
IPR036674	p53_tetramer_sf	Homologous_superfamily
IPR037612	Tumour-p73_SAM	Domain
IPR057064	P53_central_site	Conserved_site

Pfam: PF00870, PF07647, PF07710

UniProt features (71 total): strand 14, helix 13, splice variant 12, turn 7, region of interest 6, binding site 4, mutagenesis site 4, modified residue 3, cross-link 2, sequence variant 2, chain 1, domain 1, short sequence motif 1, compositionally biased region 1

Structure

Experimental structures (PDB)

28 structures.

PDB	Method	Resolution (Å)
5HOB	X-RAY DIFFRACTION	1.22
5HOC	X-RAY DIFFRACTION	1.36
2WQI	X-RAY DIFFRACTION	1.7
8P9C	X-RAY DIFFRACTION	1.76
9GNB	X-RAY DIFFRACTION	1.8
2XWC	X-RAY DIFFRACTION	1.82
2WQJ	X-RAY DIFFRACTION	2
9GLQ	X-RAY DIFFRACTION	2.1
8P9E	X-RAY DIFFRACTION	2.25
4A63	X-RAY DIFFRACTION	2.27
2WTT	X-RAY DIFFRACTION	2.3
1DXS	X-RAY DIFFRACTION	2.54
8P9D	X-RAY DIFFRACTION	2.7
5KBD	X-RAY DIFFRACTION	2.8
7EZJ	X-RAY DIFFRACTION	2.9
3VD0	X-RAY DIFFRACTION	2.95
3VD1	X-RAY DIFFRACTION	2.95
4G82	X-RAY DIFFRACTION	3.1
4GUO	X-RAY DIFFRACTION	3.19
4GUQ	X-RAY DIFFRACTION	3.7
3VD2	X-RAY DIFFRACTION	4
4G83	X-RAY DIFFRACTION	4
1COK	SOLUTION NMR
2KBY	SOLUTION NMR
2MPS	SOLUTION NMR
2NB1	SOLUTION NMR
6FGS	SOLUTION NMR
6IJQ	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15350-F1	66.25	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 194; 197; 258; 262

Post-translational modifications (5): 27, 28, 99, 627, 627

Mutagenesis-validated functional residues (4):

Position	Phenotype
27	impaired phosphorylation.
99	impaired phosphorylation of isoform beta by abl1.
487	loss of interaction with wwox.
627	strongly diminishes sumoylation but does not affect transcriptional activity.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-139915	Activation of PUMA and translocation to mitochondria
R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases
R-HSA-6803211	TP53 Regulates Transcription of Death Receptors and Ligands
R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors
R-HSA-8939236	RUNX1 regulates transcription of genes involved in differentiation of HSCs

MSigDB gene sets: 228 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_CELL_DIFFERENTIATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_DNA_DAMAGE_BY_P53_CLASS_MEDIATOR, WANG_CLIM2_TARGETS_UP, GOBP_LUNG_EPITHELIUM_DEVELOPMENT, GOBP_MUSCLE_TISSUE_DEVELOPMENT, BENPORATH_ES_WITH_H3K27ME3, BIOCARTA_ATM_PATHWAY, GOBP_REGULATION_OF_DEVELOPMENTAL_GROWTH, GOBP_LUNG_CELL_DIFFERENTIATION, GOBP_GROWTH, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER

GO Biological Process (36): kidney development (GO:0001822), release of cytochrome c from mitochondria (GO:0001836), mismatch repair (GO:0006298), inflammatory response (GO:0006954), DNA damage response (GO:0006974), regulation of mitotic cell cycle (GO:0007346), negative regulation of cell population proliferation (GO:0008285), intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630), response to xenobiotic stimulus (GO:0009410), post-embryonic development (GO:0009791), regulation of gene expression (GO:0010468), hippocampus development (GO:0021766), cerebrospinal fluid secretion (GO:0033326), intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771), regulation of apoptotic process (GO:0042981), positive regulation of MAPK cascade (GO:0043410), negative regulation of neuron apoptotic process (GO:0043524), negative regulation of neuron differentiation (GO:0045665), positive regulation of cell size (GO:0045793), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), digestive tract morphogenesis (GO:0048546), neuron development (GO:0048666), positive regulation of oligodendrocyte differentiation (GO:0048714), protein tetramerization (GO:0051262), regulation of cell cycle (GO:0051726), negative regulation of cardiac muscle cell proliferation (GO:0060044), positive regulation of lung ciliated cell differentiation (GO:1901248), positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:1902167), regulation of DNA-templated transcription (GO:0006355), apoptotic process (GO:0006915), forebrain development (GO:0030900), positive regulation of apoptotic process (GO:0043065), regulation of neuron apoptotic process (GO:0043523), positive regulation of cell differentiation (GO:0045597), positive regulation of apoptotic signaling pathway (GO:2001235)

GO Molecular Function (17): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), transcription corepressor binding (GO:0001222), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), p53 binding (GO:0002039), DNA-binding transcription factor activity (GO:0003700), protein kinase binding (GO:0019901), identical protein binding (GO:0042802), metal ion binding (GO:0046872), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), MDM2/MDM4 family protein binding (GO:0097371), DNA-binding transcription factor binding (GO:0140297), promoter-specific chromatin binding (GO:1990841), DNA binding (GO:0003677), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (10): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), Golgi apparatus (GO:0005794), centrosome (GO:0005813), cytosol (GO:0005829), plasma membrane (GO:0005886), cell junction (GO:0030054), ciliary basal body (GO:0036064), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
TP53 Regulates Transcription of Cell Death Genes	4
Activation of BH3-only proteins	1
Regulation of TP53 Activity	1
Transcriptional regulation by RUNX1	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
protein binding	3
regulation of DNA-templated transcription	2
intracellular membrane-bounded organelle	2
cytoplasm	2
microtubule organizing center	2
animal organ development	1
renal system development	1
apoptotic mitochondrial changes	1
apoptotic signaling pathway	1
DNA repair	1
defense response	1
cellular response to stress	1
mitotic cell cycle	1
regulation of cell cycle	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
DNA damage response	1
intrinsic apoptotic signaling pathway	1
response to chemical	1
multicellular organism development	1
multicellular organismal process	1
gene expression	1
regulation of macromolecule biosynthetic process	1
pallium development	1
limbic system development	1
anatomical structure development	1
body fluid secretion	1
secretion by tissue	1
intrinsic apoptotic signaling pathway in response to DNA damage	1
intrinsic apoptotic signaling pathway by p53 class mediator	1
apoptotic process	1
regulation of programmed cell death	1
MAPK cascade	1
regulation of MAPK cascade	1
positive regulation of intracellular signal transduction	1
negative regulation of apoptotic process	1
regulation of neuron apoptotic process	1

Protein interactions and networks

STRING

1689 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TP73	MDM2	Q00987	868
TP73	YAP1	P46937	843
TP73	TP63	Q9H3D4	779
TP73	RASSF1	Q9NS23	700
TP73	CDKN2A	P42771	694
TP73	RBM38	Q9H0Z9	669
TP73	MDM4	O15151	613
TP73	CDKN1A	P38936	606
TP73	ABL1	P00519	595
TP73	PMS2	P54278	588
TP73	CASP3	P42574	556
TP73	EP300	Q09472	553
TP73	PIK3CA	P42336	552
TP73	GAPDH	P00354	549
TP73	CCND1	P24385	538

IntAct

120 interactions, top by confidence:

A	B	Type	Score
TP73	TP73	psi-mi:“MI:0407”(direct interaction)	0.820
TP73	TP73	psi-mi:“MI:0915”(physical association)	0.820
TP63	TP73	psi-mi:“MI:0407”(direct interaction)	0.770
TP63	TP73	psi-mi:“MI:0915”(physical association)	0.770
TP63	TP73	psi-mi:“MI:0914”(association)	0.770
ITCH	TP73	psi-mi:“MI:0914”(association)	0.750
TP73	ITCH	psi-mi:“MI:0407”(direct interaction)	0.750
ITCH	TP73	psi-mi:“MI:0407”(direct interaction)	0.750
ITCH	TP73	psi-mi:“MI:0915”(physical association)	0.750
YAP1	TP73	psi-mi:“MI:0407”(direct interaction)	0.730
TP73	YAP1	psi-mi:“MI:0407”(direct interaction)	0.730
TP73	EP300	psi-mi:“MI:0407”(direct interaction)	0.650
EP300	TP73	psi-mi:“MI:0192”(acetylation reaction)	0.650
WWOX	TP73	psi-mi:“MI:0914”(association)	0.640
WWOX	TP73	psi-mi:“MI:0915”(physical association)	0.640
HSPA9	TP73	psi-mi:“MI:0915”(physical association)	0.640

BioGRID (511): TP73 (Affinity Capture-Western), YAP1 (Affinity Capture-Western), TP73 (Affinity Capture-MS), PLAGL1 (Affinity Capture-Western), PLAGL1 (Reconstituted Complex), TP73 (Reconstituted Complex), KAT2B (Affinity Capture-Western), EP300 (Affinity Capture-Western), PLAGL1 (Co-localization), TP73 (Co-localization), tat (Affinity Capture-Western), TP73 (Affinity Capture-Western), TP73 (Reconstituted Complex), CCNT1 (Affinity Capture-Western), TP73 (Affinity Capture-Western)

ESM2 similar proteins: A9LNK9, B2D6P4, E9Q7E2, G4N3L5, G5ED29, O15350, O45211, O61707, O95104, P14003, P15330, P20227, P23645, P29303, P34545, P47238, P49880, P53361, P98149, Q02926, Q0DA50, Q1LZF1, Q21955, Q22366, Q22703, Q29A33, Q3L1C9, Q4V3C1, Q61L47, Q68CP9, Q6C7K8, Q6E2N3, Q6YGZ4, Q7TSH6, Q7ZX03, Q8QGQ6, Q8SWR8, Q91YA8, Q91YB0, Q91YB2

Diamond homologs: O09185, O12946, O15350, O36006, O57538, O88898, O93379, P02340, P04637, P07193, P10360, P10361, P13481, P25035, P41685, P51664, P56423, P56424, P61260, P67938, P67939, P79734, P79820, P79892, Q00366, Q29480, Q29537, Q64662, Q8SPZ3, Q92143, Q95330, Q9H3D4, Q9JJP2, Q9JJP6, Q9TTA1, Q9TUB2, Q9W678, Q9W679, Q9WUR6, Q9XSK8

SIGNOR signaling

34 interactions.

A	Effect	B	Mechanism
CHEK1	up-regulates	TP73	phosphorylation
YAP1	up-regulates	TP73	binding
PLK1	down-regulates	TP73	phosphorylation
RPL11	up-regulates	TP73	binding
RPL5	up-regulates	TP73	binding
CyclinE/CDK2	down-regulates	TP73	phosphorylation
CyclinB/CDK1	down-regulates	TP73	phosphorylation
TP73	“up-regulates quantity by expression”	BBC3	“transcriptional regulation”
TP73	“up-regulates quantity by expression”	CDKN1A	“transcriptional regulation”
TP73	“up-regulates quantity by expression”	PMAIP1	“transcriptional regulation”
MDM2	“down-regulates activity”	TP73	binding
Nutlin-3	up-regulates	TP73
TP73	up-regulates	Apoptosis
TP73	up-regulates	Cell_death
ACOX1	“down-regulates quantity by destabilization”	TP73	binding
FBXO45	“down-regulates quantity by destabilization”	TP73	binding
“Cullin 1-RBX1-Skp1”	“down-regulates quantity by destabilization”	TP73	polyubiquitination
WWP1	“down-regulates quantity by destabilization”	TP73	polyubiquitination
WWP2	“down-regulates quantity by destabilization”	TP73	polyubiquitination
PRKCB	“up-regulates activity”	TP73	phosphorylation
PRKCA	“up-regulates activity”	TP73	phosphorylation
YAP/TAZ	“up-regulates activity”	TP73	binding
PLK2	“down-regulates activity”	TP73	phosphorylation
AURKA	“down-regulates activity”	TP73	phosphorylation
ITCH	“down-regulates quantity by destabilization”	TP73	ubiquitination
MAPK8	“up-regulates activity”	TP73	phosphorylation
PLK3	“down-regulates activity”	TP73	phosphorylation
CHUK	“up-regulates activity”	TP73	phosphorylation
ABL1	up-regulates	TP73	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 61 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of TP53 Activity	6	18.1×	6e-05
Cell Cycle Checkpoints	6	12.1×	3e-04
Class I MHC mediated antigen processing & presentation	6	9.6×	8e-04
Transcriptional Regulation by TP53	6	8.5×	1e-03
Cell Cycle, Mitotic	7	7.7×	7e-04
Cell Cycle	9	7.4×	1e-04
Antigen processing: Ubiquitination & Proteasome degradation	8	6.8×	5e-04

GO biological processes:

GO term	Partners	Fold	FDR
protein-containing complex assembly	5	10.7×	4e-03
protein ubiquitination	11	8.6×	3e-05
proteasome-mediated ubiquitin-dependent protein catabolic process	8	7.9×	1e-03
negative regulation of apoptotic process	8	5.2×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

134 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	1
Uncertain significance	87
Likely benign	17
Benign	13

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
1192319	NM_005427.4(TP73):c.1196+1G>A	Pathogenic
1192320	NM_005427.4(TP73):c.994C>T (p.Gln332Ter)	Pathogenic
1192321	NM_005427.4(TP73):c.1459del (p.Tyr487fs)	Pathogenic
1192322	NM_005427.4(TP73):c.613G>T (p.Glu205Ter)	Pathogenic
4076273	NM_005427.4(TP73):c.453_454del (p.Tyr152fs)	Likely pathogenic

SpliceAI

3057 predictions. Top by Δscore:

Variant	Effect	Δscore
1:3652639:CAGGT:C	donor_loss	1.0000
1:3652641:GGTAG:G	donor_loss	1.0000
1:3652642:GTA:G	donor_loss	1.0000
1:3652643:T:G	donor_loss	1.0000
1:3682332:GAGC:G	acceptor_gain	1.0000
1:3682431:G:GG	donor_gain	1.0000
1:3683052:T:A	acceptor_gain	1.0000
1:3683058:A:AG	acceptor_gain	1.0000
1:3683058:AG:A	acceptor_gain	1.0000
1:3683058:AGG:A	acceptor_gain	1.0000
1:3683059:G:A	acceptor_gain	1.0000
1:3683059:G:GA	acceptor_gain	1.0000
1:3683059:GGG:G	acceptor_gain	1.0000
1:3683059:GGGA:G	acceptor_gain	1.0000
1:3683059:GGGAA:G	acceptor_gain	1.0000
1:3683177:CATGG:C	donor_loss	1.0000
1:3683178:ATGG:A	donor_loss	1.0000
1:3683179:TGG:T	donor_loss	1.0000
1:3683182:T:A	donor_loss	1.0000
1:3707541:C:CA	acceptor_gain	1.0000
1:3707543:C:CA	acceptor_gain	1.0000
1:3707544:GCCAG:G	acceptor_loss	1.0000
1:3707547:A:AC	acceptor_loss	1.0000
1:3707547:A:AG	acceptor_gain	1.0000
1:3707548:G:GG	acceptor_gain	1.0000
1:3707548:G:GT	acceptor_loss	1.0000
1:3707548:GGC:G	acceptor_gain	1.0000
1:3707548:GGCCC:G	acceptor_gain	1.0000
1:3707791:GGTG:G	donor_loss	1.0000
1:3707792:GT:G	donor_loss	1.0000

AlphaMissense

4193 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:3707772:C:A	A137D	1.000
1:3707774:A:C	K138Q	1.000
1:3707774:A:G	K138E	1.000
1:3707775:A:T	K138M	1.000
1:3707776:G:C	K138N	1.000
1:3707776:G:T	K138N	1.000
1:3707777:T:C	S139P	1.000
1:3707781:C:A	A140D	1.000
1:3707786:T:A	W142R	1.000
1:3707786:T:C	W142R	1.000
1:3722024:T:C	S145P	1.000
1:3722025:C:T	S145F	1.000
1:3722039:A:G	K150E	1.000
1:3722043:T:C	L151P	1.000
1:3722045:T:G	Y152D	1.000
1:3722048:T:C	C153R	1.000
1:3722049:G:A	C153Y	1.000
1:3722050:C:G	C153W	1.000
1:3722066:T:C	C159R	1.000
1:3722068:C:G	C159W	1.000
1:3722121:C:A	A177D	1.000
1:3722127:C:A	P179H	1.000
1:3722132:T:G	Y181D	1.000
1:3722168:C:A	R193S	1.000
1:3722171:T:A	C194S	1.000
1:3722171:T:C	C194R	1.000
1:3722171:T:G	C194G	1.000
1:3722172:G:A	C194Y	1.000
1:3722172:G:C	C194S	1.000
1:3722172:G:T	C194F	1.000

dbSNP variants (sampled 300 via entrez): RS1000018595 (1:3708217 G>A,C), RS1000056189 (1:3673042 C>T), RS1000067675 (1:3655963 G>A), RS1000105494 (1:3703801 C>A,G), RS1000118289 (1:3736068 G>C), RS1000166688 (1:3679288 G>A), RS1000169032 (1:3670657 C>T), RS1000190268 (1:3673162 G>A), RS1000232500 (1:3736307 T>G), RS1000258436 (1:3699417 C>T), RS1000278107 (1:3706905 C>T), RS1000279599 (1:3725894 G>A,C,T), RS1000438823 (1:3702427 G>A), RS1000472343 (1:3716073 G>A,T), RS1000472658 (1:3690448 T>C)

Disease associations

OMIM: gene MIM:601990 | disease phenotypes: MIM:619466

GenCC curated gene-disease

Disease	Classification	Inheritance
ciliary dyskinesia, primary, 47, and lissencephaly	Strong	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
ciliary dyskinesia, primary, 47, and lissencephaly	Strong	AR

Mondo (2): ciliary dyskinesia, primary, 47, and lissencephaly (MONDO:0030346), respiratory failure (MONDO:0021113)

Orphanet (0):

HPO phenotypes

12 total (12 of 12 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000389	Chronic otitis media
HP:0001250	Seizure
HP:0001274	Agenesis of corpus callosum
HP:0001339	Lissencephaly
HP:0002079	Hypoplasia of the corpus callosum
HP:0002098	Respiratory distress
HP:0002110	Bronchiectasis
HP:0002205	Recurrent respiratory infections
HP:0003623	Neonatal onset
HP:0031602	Abnormal mucociliary clearance
HP:0100750	Atelectasis

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001523_38	Visceral adipose tissue adjusted for BMI	6.000000e-06
GCST001524_16	Visceral adipose tissue/subcutaneous adipose tissue ratio	2.000000e-06
GCST001525_13	Visceral fat	2.000000e-06
GCST001525_2	Visceral fat	2.000000e-06
GCST008155_41	Waist-hip ratio	3.000000e-06
GCST008992_6	Joint damage in rheumatoid arthritis	2.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0004767	visceral:subcutaneous adipose tissue ratio
EFO:0004343	waist-hip ratio
EFO:0005413	joint damage measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D012131	Respiratory Insufficiency	C08.618.846

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

93 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cisplatin	decreases expression, affects localization, increases phosphorylation, affects binding, increases activity (+7 more)	11
Arsenic Trioxide	increases cleavage, increases expression, affects cotreatment, increases activity, increases acetylation (+4 more)	6
Benzo(a)pyrene	increases expression, affects activity, affects methylation, affects cotreatment, decreases expression (+1 more)	5
sodium arsenite	affects expression, affects methylation, increases expression	4
bisphenol A	affects cotreatment, increases methylation, increases expression	3
Doxorubicin	affects binding, increases reaction, decreases reaction, affects cotreatment, increases expression (+2 more)	3
Quercetin	affects cotreatment, increases expression	3
Valproic Acid	increases methylation	3
kaempferol	increases expression	2
nickel chloride	decreases activity, affects binding, decreases reaction, increases phosphorylation	2
chrysin	increases expression	2
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	affects cotreatment, increases reaction, affects expression, decreases reaction, increases expression (+3 more)	2
bisphenol S	increases expression, decreases methylation	2
Resveratrol	increases expression, affects cotreatment, decreases expression	2
Etoposide	decreases reaction, increases activity, increases cleavage, affects reaction, increases expression (+1 more)	2
Fluorouracil	affects response to substance, increases expression, increases reaction	2
Zinc	decreases expression, affects activity, affects binding, affects folding	2
Sirolimus	affects cotreatment, increases expression, affects activity, decreases reaction, decreases expression (+3 more)	2
Luteolin	increases expression	2
cyclopiazonic acid	increases degradation	1
S63845	increases reaction, affects reaction, affects cotreatment, increases expression	1
(1R,3S,3aR,8bS)-3a-(4-Bromophenyl)-6,8-dimethoxy-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-1,8b-diol	decreases expression	1
bufotalin	increases expression	1
ethylbenzene	decreases expression, increases methylation, affects cotreatment	1
lasiocarpine	increases expression	1
myristicin	decreases expression	1
naringenin	affects cotreatment, increases expression	1
benzo(b)fluoranthene	affects cotreatment, decreases expression	1
4-biphenylamine	decreases expression	1
VX-agent	increases expression	1

Cellosaurus cell lines

10 cell lines: 7 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A7P1	SEES3-1V human TP73, clone1	Embryonic stem cell	Male
CVCL_A7P2	SEES3-1V human TP73, clone2	Embryonic stem cell	Male
CVCL_A7P3	SEES3-1V human TP73, clone3	Embryonic stem cell	Male
CVCL_B8A1	Abcam Raji TP73 KO	Cancer cell line	Male
CVCL_C0AV	Abcam THP-1 TP73 KO	Cancer cell line	Male
CVCL_C7CI	Abcam PC-3 TP73 KO	Cancer cell line	Male
CVCL_E942	YSK-21	Cancer cell line	Male
CVCL_TT49	HAP1 TP73 (-) 1	Cancer cell line	Male
CVCL_XU64	HAP1 TP73 (-) 2	Cancer cell line	Male
CVCL_XU65	HAP1 TP73 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00208078	PHASE4	TERMINATED	Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.
NCT00291460	PHASE4	UNKNOWN	Inspiratory Muscle Training in Hypercapnic COPD
NCT00355732	PHASE4	COMPLETED	Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients
NCT00560287	PHASE4	UNKNOWN	Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis
NCT00600639	PHASE4	TERMINATED	Non-Invasive Mechanical Ventilation in Elderly Patients
NCT00698958	PHASE4	COMPLETED	Ambulatory Adaptation to Non-Invasive Mechanical Ventilation
NCT00708149	PHASE4	COMPLETED	Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial
NCT00732537	PHASE4	COMPLETED	Inhaled Nitric Oxide by Oxygen Hood in Neonates
NCT00925860	PHASE4	COMPLETED	Non-Positive Pressure Ventilation in Hypoxemic Patients
NCT01204281	PHASE4	COMPLETED	Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
NCT01280019	PHASE4	UNKNOWN	FRC Guided Therapy in Acute Respiratory Failure
NCT01472302	PHASE4	COMPLETED	Closed Loop Ventilation Strategy in Intensive Care Unit (ICU) Patients
NCT01572337	PHASE4	COMPLETED	Early Non-invasive Ventilation Outside the Intensive Care Unit
NCT01941524	PHASE4	COMPLETED	Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations
NCT02203019	PHASE4	COMPLETED	Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure
NCT02491346	PHASE4	UNKNOWN	A Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU
NCT02497729	PHASE4	COMPLETED	Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial
NCT02526862	PHASE4	COMPLETED	Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation
NCT02958150	PHASE4	UNKNOWN	Dexmedetomidine Versus Standard Clinical Practice During Non Invasive Mechanical Ventilation
NCT03026777	PHASE4	COMPLETED	Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation
NCT03337373	PHASE4	COMPLETED	The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium
NCT03625687	PHASE4	TERMINATED	Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
NCT03787732	PHASE4	COMPLETED	Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation
NCT03962725	PHASE4	TERMINATED	Avoiding Neuromuscular Blockers to Reduce Complications
NCT04092621	PHASE4	UNKNOWN	Rapid Atrial Fibrillation Treatment Strategy
NCT04350086	PHASE4	WITHDRAWN	Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection
NCT04496362	PHASE4	ACTIVE_NOT_RECRUITING	Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study
NCT05277896	PHASE4	COMPLETED	Randomized Trial of Sedative Choice for Intubation
NCT05322447	PHASE4	COMPLETED	High-dose L-Carnitine and Diaphragmatic Function Assessed by Ultrasonography in Patients With Respiratory Failure.
NCT05843123	PHASE4	COMPLETED	Comparison of Gas Exchange Between Two Invasive Mechanical Ventilation Modes in Children
NCT06401083	PHASE4	RECRUITING	The Effect of an Additional Pre-extubational Loading Dose of Caffeine-citrate
NCT06881927	PHASE4	NOT_YET_RECRUITING	Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
NCT00000562	PHASE3	COMPLETED	Extracorporeal Support for Respiratory Insufficiency (ECMO)
NCT00148642	PHASE3	COMPLETED	Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)
NCT00221520	PHASE3	UNKNOWN	Sedation in the Intensive Care Unit
NCT00230984	PHASE3	COMPLETED	IRAD2 : Patients With Respiratory Failure at Home
NCT00248443	PHASE3	COMPLETED	Réa-MiniMax: Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage
NCT00347321	PHASE3	COMPLETED	Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC)
NCT00549809	PHASE3	COMPLETED	Comparison Between IMV and SIMV/PS for Ventilatory Support of Children: a Randomized Clinical Trial
NCT01076816	PHASE3	TERMINATED	Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure